Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Disease
Ocuphire Pharma announced that it will host a key opinion leader (KOL) webinar highlighting oral APX3330, its lead drug candidate for diabetic retinopathy (DR) and diabetic macular edema (DME), on Friday, October 14, 2022 at 11 am to 12:30 pm Eastern Time.
The event will feature KOLs Peter Kaiser, MD, from the Cleveland Clinic; Caroline Baumal, MD, from Tufts Medical Center; and David Lally, MD, from New England Retina Consultants. KOL presentations will set the stage for a discussion on Ocuphire’s APX3330, a first-in-class, novel orally administered small molecule inhibitor of VEGF and inflammation currently in a completed multicenter, randomized, double-masked, placebo-controlled ZETA-1 phase 2b trial for DR and DME. The discussion will highlight the unmet need and current treatment landscape for DR/DME. New data will be presented on study demographics and 24-week masked safety data from 103 enrolled diabetic retinopathy patients. The KOLs will share insights on the trial design, endpoints, and safety and efficacy expectations for a new novel oral treatment in DR. Topline results from ZETA-1 are expected later in the 4th quarter.
A live question & answer session will follow. To register for the event, click here.